Navigation Links
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
Date:12/20/2007

es of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(TM) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...tly announced that Dr. Dominique Hebrault will pre...alytical Technology (PAT) in Green Chemistry and G... (PRWEB) November 20, 2009 --...logy (PAT) in Green Chemistry and Green Engineerin...ology (PAT) case studies will be presented on how ...
(Date:11/19/2009)...all/ -- Omeros Corporation (Nasdaq: OMER ) today ...d quarter ended September 30, 2009. For the three ... net loss of $3.9 million, or $1.34 per share, as ...er share, for the same period in 2008. For the nin...orted a net loss of $15.5 million, or $5.29 per sh...
(Date:11/19/2009)...Call/ -- NeoStem, Inc. (NYSE Amex: NBS ), announc...its shareholders, discussing the Company,s acquisi...cals Holdings, Inc. (CHBP), an integrated bio-phar...of China. The merger gives NeoStem a controlling 5..., CHBP,s primary operating subsidiary and a promin...
(Date:11/19/2009)...9 MONITORING FORCE GmbH,announced ...serin in the,indication treatment-relevant levodop...phan drug status designation with the European Med...is a complication of the mainstay,treatment in adv...those,affected, since it may be disabling for the ...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
...ale, Wis. - When it comes to health information t...the "business side" of Wheaton Franciscan Healthc...and CIO of the faith-based healthcare system, has ...heaton shop. Armed with a master,s degree in busin...ource business, and now sits on Hewlett Packard,s...
...tosa, Wis. - John Psuik became a triathlon athlet...bile software products company has been engaged in...now, the route of that marathon has taken a sharp ...d owner of Developer One Software , said the comp... mobile phone provider, to include one of its newe...
...lly every area of recurring human endeavor has its..., football or racing) or work (think government wo...t when a group of people get together, they develo... can understand. The world of equity capital rais... series that I began with the Mechanics of Raisin...
Other Biology Technology:CIO Leadership Series: Greg Smith, Wheaton Franciscan Healthcare 2CIO Leadership Series: Greg Smith, Wheaton Franciscan Healthcare 3CIO Leadership Series: Greg Smith, Wheaton Franciscan Healthcare 4Milwaukee software developer gains bottom line, loses waistline 2Milwaukee software developer gains bottom line, loses waistline 3Milwaukee software developer gains bottom line, loses waistline 4Translating the language of capital-raising 2Translating the language of capital-raising 3Translating the language of capital-raising 4Translating the language of capital-raising 5Translating the language of capital-raising 6Translating the language of capital-raising 7
(Date:11/22/2009)...s at the Brain Research Centre, a partnership of t...ine and Vancouver Coastal Health Research Institut...ism by which brain cells die following a stroke, a...The results of the study were recently published o..., many brain cells continue to die even after bloo...
(Date:11/20/2009)..., Mich.---We,ve all read studies about the health ...is true at the molecular level, where amino acids ...age when single than when paired up with other cys...Michigan, along with colleagues in Belgium, have d...ingle cysteines. The research appears in the Nov. ...
(Date:11/20/2009)...gton, DC Nov. 20, 2009) Scientists from the Mari...ions of the Naval Research Laboratory (NRL) organi...ientists on an Arctic expedition to initiate metha...ermine the spatial variation of sediment contribut...S. Coast Guard Cutter Polar Sea as a research plat...
Breaking Biology News(10 mins):New understanding about mechanism for cell death after stroke leads to possible therapy 2Saving the single cysteine: New antioxidant system found 2International expedition investigates climate change, alternative fuels in Arctic 2Knowing What to Look for Can Aid in Proper Diagnosis 26 Treatment of Mild Traumatic Brain Injuries 53887 1Knowing What to Look for Can Aid in Proper Diagnosis 26 Treatment of Mild Traumatic Brain Injuries 53887 2Rapid Swine Flu Test Misses Many Infections 53883 1Rapid Swine Flu Test Misses Many Infections 53883 2Rapid Swine Flu Test Misses Many Infections 53883 3Care to Care Receives Full URAC Health Utilization Management Accreditation 53880 1Care to Care Receives Full URAC Health Utilization Management Accreditation 53880 2Care to Care Receives Full URAC Health Utilization Management Accreditation 53880 3
...en, Conn. Americans fall into six distinct groups..., and behaviors, according to a new report, "Globa...and George Mason universities. The researchers, wh...08, found that these "six Americas" include: , T...t convinced that global warming is happening, caus...
...Belgium - VIB researchers linked to K.U.Leuven and...viously believed to be useless ,junk, DNA play a v...nd that unstable pieces of junk DNA help tuning ge...to changes in their environments. The results will...cience . , Junk DNA , ,Most people do not real...
...ers at the University of California, San Francisco... linked a specialized protein in human muscles to ...ream, shedding light on what goes wrong in type 2 ...e function of this protein, which significantly is...oth the future study and possible therapies for di...
Other Biology News:From 'alarmed' to 'dismissive': The six ways Americans view global warming 2Saved by junk DNA 2UCSF discovers new glucose-regulating protein linked with diabetes 2
Rabbit Anti-CHIP Polyclonal Antibody, Unconjugated from Abcam
Tall Shaker Stand, Holds 1 Stacking Shaker from Thermo Scientific
...wo mature, well-understood technologies: grating-b...faces. This combination produces a sensitive and v...r binding events without the use of fluorescent la...e immobilized on the dotLab Sensor surface in eigh...
Heparin Clotting Assay Kit, HEPTEST from AMERICAN DIAGNOSTICA
Biology Products: